logo
Trump Administration Debt Strategy Is More Confusion And Uncertainty

Trump Administration Debt Strategy Is More Confusion And Uncertainty

Forbes31-07-2025
President Donald Trump and Treasury Secretary Scott Bessent appear to be pushing a new approach to Treasury bond sales. However, what is supposed to be new seems similar to what was done by Janet Yellen during the Biden administration: pushing short-term bonds over long-term ones.
As the Wall Street Journal reported, the administration said it would delay issuance of longer-term bonds until yields fell. The likely rationale is secondary budget control of debt expenses. Annual debt service for the U.S. is currently more expensive than any discretionary budget category, including defense spending.
'What I'm going to do is I'm going to go very short-term,' Trump had said in June, according to the Journal. 'Wait until this guy [Fed Chair Jerome Powell] gets out, get the rates way down, and then go long-term.'
The federal budget deficit is approximately $2 trillion annually. To support the deficit spending, the government must sell enough debt to cover it. The debt varies in length from far less than a month to 30-year bonds. The Treasury uses different mixes of securities to maintain the balance. Shorter-term Treasurys shorten the interest payment obligations and is usually cheaper, at least when the yield curve isn't inverted and longer-term bonds have higher yields. But shorter-term also means space for volatility and a jump in costs if inflation increases. Longer-term Treasurys allow the government to space out the debt obligations and lock in rates, but the costs are higher.
The mix typically is set and relatively consistent, so investors know what to expect. The Trump administration plans to announce on Wednesday, July 29, the mix of lengths.
'It is disingenuous to suggest this Administration is deviating from longstanding debt management practices when Treasury's auction sizes and market guidance have not changed since the last Administration,' Deputy Treasury Secretary Michael Faulkender said in a written statement, the Journal noted.
But whether a Trump or Biden administration, the strategy has become to pull back from higher levels of long-term bond sales.
Bessent, a former hedge fund manager, was a regular critic of the former administration and its Treasury Secretary Yellen for holding down sales of longer-maturity Treasurys, which affect longer-term rates for house mortgages and commercial borrowing, as Bloomberg reported in February 2025.
Currently, the combination of concern about inflation, tariff uncertainty, levels of national debt, and questions about the independence of the Feb are pushing investors to demand higher yields on the 10-year.
Bessent has said that the administration wants to push down yields on longer-term Treasury debt. So far, strategies haven't delivered. That potentially increases the amount of uncertainty the country's economy has been facing.
Announcement of tariff deals would seem to help reverse the trend of confusion, but they only appear to mask it. Jorge Liboreiro, a reporter at Euronews, posted an analysis on the White House's fact-sheet about the US-EU trade deal that, as he notes, 'with claims that directly contradict the European Commission's version of events.' One example is that the White House touts a $600 billion U.S. investment 'pledge' that the EU clarifies as an 'intention,' not pledge. There is no deal on EU purchase of U.S. military equipment. There was no concession on food safety and sanitary certificates for U.S. pork and dairy products.
Such redefinitions are more examples of sweeping problems under the rug. Even if portions of the public are reassured, investors and institutions with fiscal muscle that can affect the economy are likely not.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Cardinal Health expands urology focus with $1.9bn Solaris Health deal
Cardinal Health expands urology focus with $1.9bn Solaris Health deal

Yahoo

time13 minutes ago

  • Yahoo

Cardinal Health expands urology focus with $1.9bn Solaris Health deal

US drug distributor Cardinal Health has signed a $1.9bn agreement to acquire a majority stake in Solaris Health from Lee Equity Partners. The deal aims to expand the Specialty Alliance, the distributor's multi-speciality management services organisation (MSO) platform, in which Cardinal will gain a stake of around 75%. The acquisition will also create the Urology Alliance, comprising a collaborative network of urology providers within Cardinal's Specialty Alliance MSO, as well as resonate with plans to expand the delivery of urological patient care. Cardinal's Solaris buyout complements its recent acquisitions of Urology America, Potomac Urology, and Academic Urology & Urogynaecology, signalling its urologic strategy. The transaction is expected to be completed by the end of this year, pending customary closing conditions. Cardinal Health CEO Jason Hollar stated that growing the Speciality Alliance is a 'top priority' for the company, with the latest urology purchase leaving it 'well-positioned to meet the comprehensive needs of community urologists through the robust combined capabilities of the Specialty Alliance, Specialty Networks and Cardinal Health'. Research indicates there is a shortage of urologists in the US, with 62% of US counties lacking a practising urologist and just one new urologist entering the field for every ten retiring. The figures lead to challenges in the broader field, including delayed diagnoses, increased rates of advanced-stage conditions, and significant health disparities, with these particularly pronounced in rural communities. GlobalData's senior medical analyst Selena Yu foresees Cardinal's acquisition as reflecting a shift from drug distribution with a 'lower profit margin, towards higher margin speciality care in urology'. Yu said: 'MSOs help streamline backend work like billing and staffing to allow for physicians to focus on care. 'Additionally, with a large network of specialists, patients can receive care in the same region by different care specialists, which will reduce wait times and improve care continuity. Additionally, the Cardinal Health Alliance has other specialities like oncology specialists, which makes referrals more streamlined.' Cardinal's acquisition coincided with the release of its Q4 2025 financials. The company's profits per share came in at $2.08, beating the forecasted $2.03, yet profits for the quarter came in at $60.2bn, below the $60.92bn forecast, prompting a pre-market stock drop of more than 11% on 12 August. Cardinal's share price has since recovered to a drop of around 6% to $147.05 per share, down from $157.66 per share at market close on 11 August. "Cardinal Health expands urology focus with $1.9bn Solaris Health deal" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Effettua l'accesso per consultare il tuo portafoglio

Texas sues Eli Lilly for allegedly bribing providers to prescribe its medications
Texas sues Eli Lilly for allegedly bribing providers to prescribe its medications

Yahoo

time13 minutes ago

  • Yahoo

Texas sues Eli Lilly for allegedly bribing providers to prescribe its medications

WASHINGTON (Reuters) -Texas Attorney General Ken Paxton on Tuesday sued U.S. drugmaker Eli Lilly for allegedly "bribing" providers to prescribe its medications. The attorney general's office said in a statement that the company bribed and illegally induced medical providers to prescribe its most profitable drugs, including the GLP-1 medications Mounjaro and Zepbound, used for weight loss and diabetes treatment. "Big Pharma compromised medical decision-making by engaging in an illegal kickback scheme," Attorney General Paxton said. The lawsuit builds upon Attorney General's previous legal action to hold drug manufacturers accountable for fraud and abuse, the statement added. Last year, Paxton had sued insulin manufacturers, including Lilly and pharmacy benefit managers (PBMs), alleging that manufacturers artificially raised the prices of insulin and then paid a significant, undisclosed portion back to the PBMs for preferential treatment in return. Eli Lilly did not immediately respond to a Reuters request for comment. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Trump Floats Deal to Let Nvidia's Blackwell Chips Into China -- With a 50% Power Cut
Trump Floats Deal to Let Nvidia's Blackwell Chips Into China -- With a 50% Power Cut

Yahoo

time13 minutes ago

  • Yahoo

Trump Floats Deal to Let Nvidia's Blackwell Chips Into China -- With a 50% Power Cut

President Donald Trump has signaled he may be open to letting Nvidia (NASDAQ:NVDA) ship a toned-down version of its most advanced Blackwell AI chip to China if the company trims its capabilities by 30% to 50%. The comment comes shortly after Trump confirmed an unusual arrangement already in place for Nvidia's less-powerful H20 chip, which allows exports to China in exchange for a 15% revenue share paid directly to the US government. Advanced Micro Devices will follow the same formula for its MI308 chip, according to a person familiar with the matter. Nvidia has not commented on the president's remarks. Warning! GuruFocus has detected 5 Warning Signs with NVDA. The potential deal for Blackwell would mirror Trump's broader push to secure financial returns for the US in exchange for loosening certain export restrictions a strategy that could influence how American companies negotiate market access in China. While Trump didn't outline a specific timeline, he suggested Nvidia CEO Jensen Huang could soon meet with him to discuss a negatively enhanced Blackwell variant. If approved, the move could mark a shift in how high-end US chip technology is selectively offered abroad. Nvidia's Blackwell chips are the backbone of today's most powerful AI systems but remain off-limits to China under current US rules. Both Nvidia and AMD (NASDAQ:AMD) have taken revenue hits as tighter controls limited exports to older models on par with domestic Chinese alternatives products that have struggled to gain traction. Nvidia has already said it is developing another China-specific chip and will seek approval to sell it. The company noted that further cutting back its Hopper-based H20 chip is no longer viable, suggesting a modified Blackwell could be the clearest path to regaining momentum in one of the world's largest AI markets. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store